Ozempic (semaglutide) is not approved for use during pregnancy and is generally not recommended when trying to conceive or during pregnancy. Currently classified as FDA Pregnancy Category C based on older animal studies, and more recent human data are limited. Because semaglutide crosses the placenta and may affect fetal growth and glucose metabolism, major guidelines typically advise avoiding it in pregnancy and switching to preferred alternatives with longer safety records. This evergreen explainer covers key definitions, background, what is known about risks, monitoring considerations, and alternative medications that are commonly recommended during pregnancy.
Key Definitions and Background
Ozempic is a once-weekly injectable prescription medicine that contains semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) originally developed for type 2 diabetes and weight management. It lowers blood sugar primarily by increasing insulin secretion, decreasing glucagon release, and slowing gastric emptying. It is not the same as insulin and is not indicated for use in pregnancy. In the United States, Ozempic is approved for adults with type 2 diabetes and for adults with obesity or overweight with at least one weight-related condition; it is not approved for use in people who are pregnant.
FDA Pregnancy Categories and Current Regulatory Status
Regulatory classifications provide a high-level summary of evidence, but they do not capture nuanced, real-world risk. Below is an at-a-glance status for semaglutide products in pregnancy.
| Product | FDA Pregnancy Category* | Notes and Source Type |
|---|---|---|
| Ozempic (semaglutide) | C | Animal studies; human data limited; not indicated in pregnancy |
| Rybelsus (oral semaglutide) | C | Oral formulation; similar considerations |
| Wegovy (semaglutide higher dose) | C | Weight management formulation; pregnancy use not recommended |
*FDA categories are being phased out in labeling but remain familiar reference points; they summarize potential benefit versus risk based on available data.
What Is Known About Risks in Human Pregnancy
Human data on semaglutide use during pregnancy are limited and mostly observational. Based on existing reports and pharmacologic class effects, clinicians and guidelines generally note the following points of caution:
- Semaglutide crosses the placenta, so fetal exposure is expected if used in pregnancy.
- There are postmarketing reports describing pregnancies exposed to semaglutide, with some noted outcomes including preterm birth and fetal growth changes, but these observations do not establish causation.
- High maternal blood sugar (hyperglycemia) poses clear risks to pregnancy and fetal development; therefore, optimizing glucose control before and during pregnancy is important regardless of medication.
Typical Guidance in Medical Guidelines
Major endocrine, obstetric, and diabetes societies generally advise that semaglutide and similar medications not be used during pregnancy. If a person becomes pregnant while using Ozempic, recommendations usually include:
- Stop Ozempic as soon as pregnancy is confirmed, under clinician supervision.
- Switch to an insulin regimen or other medications with more established pregnancy safety profiles.
- Increase prenatal monitoring, including detailed anatomy imaging and growth surveillance, to detect any abnormalities early.
Preferred Alternatives During Pregnancy
For people with diabetes or obesity who are planning pregnancy or become pregnant, many clinicians favor therapies with longer pregnancy use histories and clearer regulatory classifications in some regions. Alternatives to semaglutide include:
- Insulin: The most widely studied and recommended glucose-lowering medication in pregnancy; it does not cross the placenta.
- Metformin: Often used, especially for gestational diabetes or polycystic ovary syndrome (PCOS), and considered acceptable in many regions, though it does cross the placenta more than insulin.
- Certain sulfonylureas: Used in specific situations when metformin is not suitable; choice depends on individual factors and local guidelines.
The choice of therapy is highly individualized, taking into account the type and severity of diabetes, prior medications, comorbidities, and shared decision-making with the care team.
Practical Steps for People Who Are or May Become Pregnant
Planning and proactive communication with clinicians improve outcomes. Consider the following steps:
- Preconception counseling: Review current medications and aim for target glucose levels before conception.
- Pregnancy testing: Use reliable contraception until transitioning off Ozempic and until an alternative plan is in place if pregnancy avoidance is desired.
- Timely transition: If trying to conceive or once pregnancy is confirmed, work with a clinician to switch to an appropriate regimen early.
- Prenatal follow-up: Attend all scheduled visits and monitoring, including anatomy ultrasound and growth scans, as recommended.
Monitoring and Follow-Up Considerations
After discontinuation of Ozempic and initiation of an alternative regimen, ongoing monitoring is essential. Standard prenatal care usually includes glucose testing for gestational diabetes, fetal anatomy ultrasound, and serial growth ultrasounds. For people with preexisting diabetes, additional monitoring may include:
- Hemoglobin A1c trends in early pregnancy.
- Home blood glucose logs.
- Fetal growth scans at regular intervals.
- Assessment for congenital anomalies, if indicated based on history or first-trimester findings.
When to Seek Immediate Care
Pregnant people using any glucose-lowering medication should seek prompt medical attention for concerning symptoms such as very low blood sugar (prolonged dizziness, confusion, fainting, severe sweating), signs of infection, sudden vision changes, or decreased fetal movement. These situations require evaluation regardless of the specific medication used.